<DOC>
	<DOCNO>NCT00031642</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell deliver cancer-killing substance without harm normal cell . Radiolabeled monoclonal antibody locate deliver radioactive cancer-killing substance . PURPOSE : Phase I/II trial study effectiveness combine radiolabeled monoclonal antibody rituximab treat patient non-Hodgkin 's lymphoma respond high-dose chemotherapy autologous stem cell transplantation .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma That Has Relapsed After High-Dose Chemotherapy Autologous Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90-labeled ibritumomab tiuxetan administer rituximab patient B-cell non-Hodgkin 's lymphoma relapse high-dose chemotherapy autologous hematopoietic stem cell transplantation . - Determine safety efficacy regimen patient . OUTLINE : This dose-escalation study yttrium Y 90-labeled ibritumomab tiuxetan ( IDEC-Y2B8 ) . - Phase I : Patients receive rituximab IV 4-6 hour follow indium In 111-labeled ibritumomab tiuxetan ( IDEC-In2B8 ) IV 10 minute day 0 . Patients receive rituximab IV day 7 follow IDEC-Y2B8 IV 10 minute . Cohorts 3-6 patient receive escalate dos IDEC-Y2B8 maximum tolerate dose ( MTD ) determine . The MTD define dose 3 6 patient experience dose-limiting toxicity . - Phase II : Once MTD determine , 58 additional patient treat dose level phase I . Patients follow 6 week , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 78 patient ( 20 phase I 58 phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse Bcell nonHodgkin 's lymphoma ( NHL ) highdose chemotherapy autologous stem cell transplantation Less 25 % bone marrow involvement NHL evidence unilateral bilateral biopsy within past 6 week Bone marrow biopsy demonstrate 1520 % cellular space occupy normal hematopoiesis CD20 antigen expression tumor tissue within past year evidence 1 following : Immunoperoxidase stain tissue show positive reactivity L26 antibody Flow cytometry study Measurable disease More 2 cm bidimensionally No active CNS lymphoma No HIV AIDSrelated lymphoma PATIENT CHARACTERISTICS : Age : 19 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 150,000/mm^3 No transfusion dependency Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT great 2.5 time upper limit normal ( unless due lymphomatous infiltration liver ) Renal : Creatinine le 2.0 mg/dL No active obstructive hydronephrosis Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study therapy HIV negative No active infection require oral IV antibiotics No human antimurine antibody positivity No major medical problem PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior growth factor At least 4 week since prior biologic therapy No dependency hematopoietic growth factor ( e.g. , epoetin alfa , interleukin11 , filgrastim [ GCSF ] , sargramostim [ GMCSF ] ) No prior radioimmunotherapy No concurrent biologic therapy kind Chemotherapy : See Disease Characteristics At least 4 week since prior cytotoxic chemotherapy ( 6 week nitrosoureas ) No prior fludarabine No concurrent chemotherapy Endocrine therapy : No concurrent steroid except maintenance noncancerous disease Radiotherapy : See Biologic therapy At least 4 week since prior radiotherapy No prior pelvic radiotherapy No prior radiotherapy 25 % estimate bone marrow reserve No concurrent external beam radiotherapy Surgery : Not specify Other : Recovered prior therapy At least 4 week since prior immunosuppressant No concurrent investigational drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>